You are here
Head-To-Head Study of Osteoporosis Therapies Announced
The MOTION trial (Monthly Oral Therapy with Ibandronate for Osteoporosis INtervention), a non-inferiority study, will compare the efficacy and safety of once-monthly oral Bonivaand weekly oral Fosamax.1 The MOTION study design was presented today at the 27th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR).
“This is a very important study because these two treatment regimens have never before been directly compared,” said Felicia Cosman, M.D., medical director of the ClinicalResearchCenter, Helen Hayes Hospital in West Haverstraw, NY. “This trial will measure each treatment’s ability to increase bone mineral density, an accepted surrogate for determining the risk of fracture -- the most relevant consequence of postmenopausal osteoporosis.”
“We are confident that the large head-to-head study between Boniva and Fosamax will help physicians choose the treatment option that will meet their patients’ needs,” stated Keith E. Friend, M.D., senior medical director, Roche.
The MOTION trial is designed to compare the efficacy of once-monthly oral ibandronate with weekly oral alendronate. In MOTION, a randomized, double-blind, double-dummy study, close to 1,900 women with postmenopausal osteoporosis will receive either 150 mg once-monthly oral ibandronate or 70 mg once-weekly oral alendronate for one year. To maintain blinding, participants will also receive once-monthly or weekly oral placebo, plus daily calcium (500-1500 mg) and vitamin D (400 IU). The primary endpoints are percent change from baseline in lumbar spine and total hip bone mineral density (BMD) at one year. Secondary endpoints include percent change in hip trochanter BMD at one year and biochemical markers of bone turnover in a subset of patients at day seven and months three, six and 12. Clinical vertebral and non-vertebral fractures will also be assessed, and their respective rates compared. Adverse events will be monitored throughout the study.
Osteoporosis (porous bones) is a disease in which bones become brittle and more likely to break. In the U.S. today, 10 million individuals, eight million of whom are women, are estimated to already have osteoporosis, and almost 34 million more are estimated to have low bone mass (osteopenia),placing them at increased risk for osteoporosis. Unfortunately, the prevalence of osteoporosis is growing, especially as the number of postmenopausal women in the population continues to rise. Together, osteoporosis and osteopenia are expected to affect an estimated 52 million women and men age 50 and older by 2010, and 61 million by 2020.4 Direct medical costs of osteoporosis total nearly $18 billion in the U.S.each year.
About Once-Monthly Oral Boniva
Once-monthly Boniva is a small, film-coated, easy-to-swallow tablet dosed at 150 mg. Patients should take Boniva with plain water on an empty stomach upon rising in the morning. They should remain upright and avoid food, drink and other medications for at least 60 minutes.
Patients who take Bonivaare eligible to sign up for MyBONIVA, a program designed to help enhance compliance (taking therapy as directed) and persistence (staying on therapy) with this unique once-monthly regimen. For more information on this program call 1-800-4BONIVA or visit www.myboniva.com.
Important Safety Information
Boniva is contraindicated in patients unable to stand or sit upright for at least 60 minutes, with uncorrected hypocalcemia, or with known hypersensitivity to any component of Boniva. Boniva, like other bisphosphonates administered orally, may cause upper gastrointestinal disorders such as dysphagia, esophagitis, and esophageal or gastric ulcer. Bonivais not recommended in patients with severe renal impairment. Adequate intake of calcium and Vitamin D is important in all patients.
Rarely, patients have reported severe bone, joint and/or muscle pain after taking bisphosphonate therapy for osteoporosis. Additionally, osteonecrosis of the jaw has rarely been reported in patients treated with bisphosphonates; most cases have been in cancer patients undergoing dental procedures. The most commonly reported adverse events with once-monthly Bonivaregardless of causality were abdominal pain (Boniva150 mg 7.8 percent vs. Boniva2.5 mg 5.3 percent), hypertension (6.3 percent vs. 7.3 percent), dyspepsia (5.6 percent vs. 7.1 percent), arthralgia (5.6 percent vs. 3.5 percent), nausea (5.1 percent vs. 4.8 percent) and diarrhea (5.1 percent vs. 4.1 percent).
For complete prescribing information for BonivaTablets, see contact information at the end of the news release or go to www.boniva.com.
1. Cosman F, McClung M, Rosen C, Epstein S, Devas V, El Azzouzi B, Bonvoisin B, Zanchetta J, Cooper C, Delmas PD. Rationale And Design Of The MOTION Study (Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention). Poster M359 presented at: 27th Annual Meeting of the American Society for Bone Mineral Research, September 23-27, 2005, Nashville, TN.
2. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation: The National Osteoporosis Foundation; February 2002.
3. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S.Department of Health and Human Services, Office of the Surgeon General; 2004.